1. Epigallocatechin gallate protects mice from Salmonella enterica ser. Typhimurium infection by modulating bacterial virulence through quorum sensing inhibition.
- Author
-
Cheng G, Jian S, Li W, Yan L, Chen T, Cheng T, Liu Z, Ye G, Tang H, and Zhang L
- Subjects
- Animals, Mice, Virulence drug effects, Gene Expression Regulation, Bacterial drug effects, Salmonella Infections microbiology, Salmonella Infections drug therapy, Bacterial Proteins metabolism, Bacterial Proteins genetics, Virulence Factors genetics, Virulence Factors metabolism, Female, Type III Secretion Systems drug effects, Type III Secretion Systems metabolism, Type III Secretion Systems genetics, Mice, Inbred BALB C, Genomic Islands, Flagella drug effects, Intestines microbiology, Anti-Bacterial Agents pharmacology, Catechin analogs & derivatives, Catechin pharmacology, Quorum Sensing drug effects, Salmonella typhimurium drug effects, Salmonella typhimurium pathogenicity, Salmonella typhimurium genetics, Disease Models, Animal, Biofilms drug effects
- Abstract
Salmonella enterica ser. Typhimurium is a common pathogen that poses a considerable public health threat, contributing to severe gastrointestinal diseases and widespread foodborne illnesses. The virulence of S. Typhimurium is regulated by quorum sensing (QS) and the type III secretion system (T3SS). This study investigated the inhibitory effects and anti-QS activity of epigallocatechin gallate (EGCG), which is a bioactive ingredient found in green tea, on the virulence of S. Typhimurium. In vitro bacterial experiments demonstrated that EGCG inhibited the production of autoinducers, biofilm formation, and flagellar activity by downregulating the expression of AI-1, AI-2, Salmonella pathogenicity islands (SPI)-1, SPI-2, and genes related to flagella, fimbriae, and curli fibers. In a mouse model of S. Typhimurium-induced enteritis, EGCG considerably reduced intestinal colonization by S . Typhimurium and alleviated intestinal damage. In conclusion, EGCG protects the intestines of mice infected with S. Typhimurium by inhibiting QS-induced virulence gene expression, demonstrating its potential as a therapeutic agent for controlling S. Typhimurium infections., Competing Interests: Author ZL was employed by the company Chengdu Qiankun Animal Pharmaceutical Co., Ltd. The remaining authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Cheng, Jian, Li, Yan, Chen, Cheng, Liu, Ye, Tang and Zhang.)
- Published
- 2024
- Full Text
- View/download PDF